ALACHUA, Fla.--(BUSINESS WIRE)--Banyan Biomarkers, Inc., the leader in developing in vitro diagnostic products to address unmet clinical needs for the detection of traumatic brain injury, announced today the appointment of Jackson Streeter, M.D. as Chief Executive Officer and Chief Medical Officer. Dr. Streeter will relocate to Gainesville, Florida from San Diego, California where he served most recently as the Founder and Chief Scientific Officer of PhotoThera, Inc., a medical device company investigating the use of light energy to treat various diseases and health conditions. Dr. Streeter will continue to serve as an advisor to PhotoThera and be a Steering Committee member for its NEST-3 Pivotal Clinical Study for the treatment of ischemic stroke.
“Dr. Streeter’s combination of medical knowledge and his experience as a seasoned medical device executive will serve Banyan Biomarkers well as we accelerate the development and clinical potential of our diagnostic products.”
Ronald L. Hayes, PhD, Co-Founder and Chairman of the Board of Directors of Banyan Biomarkers commented, “Dr. Streeter’s combination of medical knowledge and his experience as a seasoned medical device executive will serve Banyan Biomarkers well as we accelerate the development and clinical potential of our diagnostic products.”
Dr. Streeter earned his B.S. degree in Biology from the University of Nevada Reno and his M.D. from the University of Nevada School of Medicine. Before founding PhotoThera and serving as President and Chief Executive Officer from 2002 to 2006, Dr. Streeter served as an Officer in the U.S. Navy, completing a general surgery internship at Naval Regional Medical Center Portsmouth, Virginia and then primary Flight School at Naval Air Station Pensacola, Florida. During his military service Streeter was the first Naval Flight Surgeon selected as a TOPGUN staff instructor.
About Banyan Biomarkers
Banyan Biomarkers is the leader in developing in vitro diagnostic products to address unmet clinical needs for the detection of traumatic brain injury. The Company is focused on developing a simple point-of-care blood test that will be used by physicians to detect the presence and severity of brain trauma and improve the medical management of head injured patients. Banyan Biomarkers has a licensing agreement with the University of Florida for exclusive global use of technology related to this product. To learn more about Banyan Biomarkers, Inc., visit http://www.banyanbio.com.
Banyan Biomarkers, Inc.
Linda Garcia, Director, Corporate Communications